-
Aug 13, 2024 | 
bioprocessonline.com | Jon C. Strauss |Cory Lewis |Incog BioPharma
Discover the new speed of analytical testing services with KBI Biopharma's Analytics Portal – your single access point for quoting, ordering, sample submission, project status tracking, and data access. Leverage our global expertise in biopharmaceutical analytics to support you through every phase of your project, from early-stage development to commercialization. Skip the back-and-forth emails with your service provider. Simply log in and get everything done. Learn more here.
-
Jul 15, 2024 | 
news-journal.com | Incog BioPharma
FISHERS, Ind. , July 15, 2024 /PRNewswire/ -- INCOG BioPharma Services, a contract development and manufacturing organization (CDMO) specializing in sterile injectable biopharmaceuticals, is excited to announce a new investment to expand its manufacturing capabilities. The expansion includes the construction of a second 100,000-square-foot building on its campus, set to break ground in August.
-
Jul 2, 2024 | 
bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Cory Lewis |Incog BioPharma
Webinar: Accelerating Drug Development for Biologics: Flexible and Fast DNA-to-IND ProgramsJoin us on July 8th with Lonza to explore innovative strategies and good practices to accelerate the pathway to clinic, increase specific productivity, and enhance product yield.
-
Jun 20, 2024 | 
outsourcedpharma.com | Louis Garguilo |Cory Lewis |Incog BioPharma
Webinar: Key Elements of Process and Analytical Development to Support Biologics Tech TransferIn this webinar our expert panel discusses the intricacies of technology transfer, drawing from real-life case studies. Investigate critical components for success, risk assessment, and effective mitigation strategies. Learn how to optimize your timeline and enhance efficiency in your transfer processes. Click here to learn more.
-
Apr 30, 2024 | 
easternprogress.com | Incog BioPharma
Achieves FDA Approval for Sterile Injectable Drug Product Manufacturing, /PRNewswire/ -- INCOG BioPharma Services proudly announces that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product. The regulatory approval for its customer signifies a significant milestone for INCOG, as it positions itself as an emerging leader in the biopharmaceutical contract manufacturing industry.
-
Apr 8, 2024 | 
outsourcedpharma.com | Erich Bozenhardt |Doug Dayhoff |Incog BioPharma |Louis Garguilo
Don't get trapped in the misconception that only biomanufacturing process systems need maintenance. Here are some real-life examples of facility maintenance programs gone wrong. Inclusion Bodies: Mother Nature's Help Or Hindrance? The pros and cons of soluble and insoluble processes: isolating, solubilizing and properly refolding, and strategies to improve the performance of IB processes.
-
Feb 16, 2024 | 
bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Cory Lewis |Incog BioPharma
AAV-vectored drugs can potentially treat population-level diseases. But biopharmaceutical companies will have to get better at producing them in bulk. Here are some areas to focus on. Delivering On-Time, Every Time: 4 Key Factors For Evaluating A CDMOReview four key factors for improving on-time delivery when outsourcing drug product manufacturing and discover how investing in building a solid relationship with your CDMO improves timelines.
-
Feb 15, 2024 | 
ktla.com | Incog BioPharma
, /PRNewswire/ -- INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity. This second filling line will be delivered on site this summer and qualified for GMP production in Q2 of 2025.
-
Oct 26, 2023 | 
outsourcedpharma.com | Louis Garguilo |Aashi Mishra |Cory Lewis |Incog BioPharma
Things are moving relatively quickly at NervGen, but CEO Michael Kelly took time to speak about his outsourcing experiences and best practices for "hiring" external partners such as CDMOs.September 2023: CDMO Opportunities And Threats ReportEach month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers.
-
Oct 16, 2023 | 
outsourcedpharma.com | Cory Lewis |Incog BioPharma |Louis Garguilo
Article
| October 16, 2023
By Cory Lewis, Chief Executive Officer and President, INCOG BioPharma Services
Meeting delivery timelines is a critical requirement for biopharma companies bringing a product to market. Receiving the drug “on time, every time” from an outsourcing partner is a challenging factor, according to customer surveys published in the “CDMO Outsourcing Models Edition” by ISR Reports.
